OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Balar on the Future of Immunotherapy in Bladder Cancer

May 29th 2019

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the future of immunotherapy in bladder cancer.

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

May 29th 2019

Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

May 29th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of durvalumab in stage III non–small cell lung cancer.

Dr. Clarke Compares TKIs in EGFR+ NSCLC

May 29th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, compares EGFR TKIs in EGFR-positive non–small cell lung cancer.

Dr. Antonia on the Promise of Immunotherapy in NSCLC

May 29th 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses the promise of immunotherapy in patients with non–small cell lung cancer.

Dr. LaCasce Discusses the FDA Approval of Lenalidomide/Rituximab in Non-Hodgkin Lymphoma

May 28th 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the FDA approval of lenalidomide (Revlimid) and rituximab (Rituxan; R2) in non-Hodgkin lymphoma.

Dr. Wang Discusses the Future of Treatment in MCL

May 24th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

Dr. Sabbatini on Frontline Treatment of Newly Diagnosed Ovarian Cancer

May 24th 2019

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.

Dr. Barrientos on Remaining Challenges in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses remaining challenges in the treatment of patients with chronic lymphocytic leukemia.

Dr. McGregor on the Future of Cabozantinib in RCC

May 24th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Dr. Powles on PD-L1 as a Biomarker in RCC

May 24th 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the use of PD-L1 as a biomarker in renal cell carcinoma (RCC).

Dr. Mortimer on Brain Metastases in HER2+ Breast Cancer

May 24th 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

Dr. Backes on the Utility of Sentinel Lymph Node Mapping in Cervical Cancer

May 24th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the utility of sentinel lymph node mapping in patients with cervical cancer.

Dr. Anthony on Spartalizumab in NETs

May 24th 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).

Dr. Bianchi on Maintenance Therapy in Multiple Myeloma

May 24th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses maintenance therapy in the treatment of patients with multiple myeloma.

Dr. Langer Discusses the Use of NGS in NSCLC

May 23rd 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the use of next-generation sequencing in non–small cell lung cancer.

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

May 23rd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.

Dr. El-Rayes on Locoregional Therapy Versus Resection in CRC

May 23rd 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses considerations for locoregional therapy versus resection in patients with colorectal cancer.

Dr. Hari on Current State of Frontline Therapy in Myeloma

May 23rd 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

Dr. Khan on Implications of the REFLECT Trial in HCC

May 23rd 2019

Gazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses the implications of the REFLECT trial in advanced hepatocellular carcinoma (HCC).